Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages.

Journal for immunotherapy of cancer - 1 Mar 2021

Ou Da-Liang, Chen Chia-Wei, Hsu Chia-Lang, Chung Chih-Hung, Feng Zi-Rui, Lee Bin-Shyun, Cheng Ann-Lii, Yang Muh-Hwa, Hsu Chiun

Abstract excerpt

BACKGROUND: Regorafenib and other multikinase inhibitors may enhance antitumor efficacy of anti-program cell death-1 (anti-PD1) therapy in hepatocellular carcinoma (HCC). Its immunomodulatory effects, besides anti-angiogenesis, were not clearly defined. METHODS: In vivo antitumor efficacy was tested in multiple syngeneic liver cancer models. Murine bone marrow-derived macrophages (BMDMs) were tested in vitro for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Coculture Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclic AMP Response Element-Binding Protein

Share to Kruppel-Like Factor 4

Share to Lymphocytes, Tumor-Infiltrating

Share to p38 Mitogen-Activated Protein Kinases

Share to Phenylurea Compounds

Share to Tumor-Associated Macrophages

Source

Open in PubMed Open full text

Identifiers

PMID: 33753566
DOI: 10.1136/jitc-2020-001657
PMCID: PMC7986673

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages.PMID 33753566Read ↗

Bufalin stimulates antitumor immune response by driving tumor-infiltrating macrophage toward M1 phenotype in hepatocellular carcinoma.Semantic proximity Read ↗

Regorafenib enhances antitumor immune efficacy of anti-PD-L1 immunotherapy on oral squamous cell carcinoma.Semantic proximity Read ↗

Colony-Stimulating Factor 1 Receptor Blockade Inhibits Tumor Growth by Altering the Polarization of Tumor-Associated Macrophages in Hepatocellular Carcinoma.Semantic proximity Read ↗

Gefitinib inhibits M2-like polarization of tumor-associated macrophages in Lewis lung cancer by targeting the STAT6 signaling pathway.Semantic proximity Read ↗

Molecular insight of regorafenib treatment for colorectal cancer.Semantic proximity Read ↗

Different Mechanisms of Action of Regorafenib and Lenvatinib on Toll-Like Receptor-Signaling Pathways in Human Hepatoma Cell LinesSemantic proximity Read ↗

Sophora tonkinensis reprograms tumor-associated macrophages to M1-like phenotype and exerts anti-hepatocellular carcinoma effects.Semantic proximity Read ↗

High-throughput heterospheroid-based screening identifies drugs that reprogram tumor-associated macrophagesSemantic proximity Read ↗

The CSF-1R inhibitor Pexidartinib impacts dendritic cell differentiation through inhibition of FLT3 signaling and may antagonize the effect of durvalumab in patients with advanced cancer – results from a phase 1 studySemantic proximity Read ↗

M2 macrophages contribute to cell proliferation and migration of breast cancerSemantic proximity Read ↗

Colony-stimulating factor-1-induced AIF1 expression in tumor-associated macrophages enhances the progression of hepatocellular carcinomaSemantic proximity Read ↗

The chemical biology of IL-12 production via the non-canonical NFkB pathwaySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.